Sequenom Inc. Launches Safer Diagnostic Test for Down Syndrome

San Diego-based Sequenom (NASDAQ: SQNM) says today it’s making a prenatal test for fetal Down syndrome available in 20 U.S. cities, 2 1/2 years after the company shelved the debut of an earlier Down syndrome test due to “mishandled” research data. The proprietary test announced today is a laboratory-developed test (LDT) that detects an abnormal chromosome for Down syndrome in the fetal DNA fragments found in a maternal blood sample. A Sequenom-funded study that confirms that the technique is 99.1 percent accurate also is being published in the journal Genetics in Medicine by an independent group of researchers.

Back to news